147 related articles for article (PubMed ID: 25388286)
1. SYK is a candidate kinase target for the treatment of advanced prostate cancer.
Ghotra VP; He S; van der Horst G; Nijhoff S; de Bont H; Lekkerkerker A; Janssen R; Jenster G; van Leenders GJ; Hoogland AM; Verhoef EI; Baranski Z; Xiong J; van de Water B; van der Pluijm G; Snaar-Jagalska BE; Danen EH
Cancer Res; 2015 Jan; 75(1):230-40. PubMed ID: 25388286
[TBL] [Abstract][Full Text] [Related]
2. Anti-inflammatory actions of Syk inhibitors in macrophages involve non-specific inhibition of toll-like receptors-mediated JNK signaling pathway.
Lin YC; Huang DY; Chu CL; Lin WW
Mol Immunol; 2010 Apr; 47(7-8):1569-78. PubMed ID: 20138367
[TBL] [Abstract][Full Text] [Related]
3. The tyrosine kinase Syk regulates the survival of chronic lymphocytic leukemia B cells through PKCdelta and proteasome-dependent regulation of Mcl-1 expression.
Baudot AD; Jeandel PY; Mouska X; Maurer U; Tartare-Deckert S; Raynaud SD; Cassuto JP; Ticchioni M; Deckert M
Oncogene; 2009 Sep; 28(37):3261-73. PubMed ID: 19581935
[TBL] [Abstract][Full Text] [Related]
4. Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis.
Coffey G; DeGuzman F; Inagaki M; Pak Y; Delaney SM; Ives D; Betz A; Jia ZJ; Pandey A; Baker D; Hollenbach SJ; Phillips DR; Sinha U
J Pharmacol Exp Ther; 2012 Feb; 340(2):350-9. PubMed ID: 22040680
[TBL] [Abstract][Full Text] [Related]
5. Increased SYK activity is associated with unfavorable outcome among patients with acute myeloid leukemia.
Boros K; Puissant A; Back M; Alexe G; Bassil CF; Sinha P; Tholouli E; Stegmaier K; Byers RJ; Rodig SJ
Oncotarget; 2015 Sep; 6(28):25575-87. PubMed ID: 26315286
[TBL] [Abstract][Full Text] [Related]
6. Spleen tyrosine kinase mediates high glucose-induced transforming growth factor-β1 up-regulation in proximal tubular epithelial cells.
Yang WS; Chang JW; Han NJ; Lee SK; Park SK
Exp Cell Res; 2012 Sep; 318(15):1867-76. PubMed ID: 22659134
[TBL] [Abstract][Full Text] [Related]
7. Syk tyrosine kinase is linked to cell motility and progression in squamous cell carcinomas of the head and neck.
Luangdilok S; Box C; Patterson L; Court W; Harrington K; Pitkin L; Rhŷs-Evans P; O-charoenrat P; Eccles S
Cancer Res; 2007 Aug; 67(16):7907-16. PubMed ID: 17699797
[TBL] [Abstract][Full Text] [Related]
8. Spleen tyrosine kinase mediates BEAS-2B cell migration and proliferation and human rhinovirus-induced expression of vascular endothelial growth factor and interleukin-8.
Wang X; Mychajlowycz M; Lau C; Gutierrez C; Scott JA; Chow CW
J Pharmacol Exp Ther; 2012 Feb; 340(2):277-85. PubMed ID: 22031919
[TBL] [Abstract][Full Text] [Related]
9. SYK inhibition and response prediction in diffuse large B-cell lymphoma.
Cheng S; Coffey G; Zhang XH; Shaknovich R; Song Z; Lu P; Pandey A; Melnick AM; Sinha U; Wang YL
Blood; 2011 Dec; 118(24):6342-52. PubMed ID: 22025527
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic prospect of Syk inhibitors.
Ruzza P; Biondi B; Calderan A
Expert Opin Ther Pat; 2009 Oct; 19(10):1361-76. PubMed ID: 19670961
[TBL] [Abstract][Full Text] [Related]
11. Can treating the SYK cell cure leukemia?
Downing JR
Cancer Cell; 2009 Oct; 16(4):270-1. PubMed ID: 19800569
[TBL] [Abstract][Full Text] [Related]
12. Kinetic assay for characterization of spleen tyrosine kinase activity and inhibition with recombinant kinase and crude cell lysates.
Li M; Luraghi P; Amour A; Qian XD; Carter PS; Clark CJ; Deakin A; Denyer J; Hobbs CI; Surby M; Patel VK; Schaefer EM
Anal Biochem; 2009 Jan; 384(1):56-67. PubMed ID: 18762159
[TBL] [Abstract][Full Text] [Related]
13. Spleen tyrosine kinase (Syk) is a potent target for GvHD prevention at different cellular levels.
Leonhardt F; Zirlik K; Buchner M; Prinz G; Hechinger AK; Gerlach UV; Fisch P; Schmitt-Gräff A; Reichardt W; Zeiser R
Leukemia; 2012 Jul; 26(7):1617-29. PubMed ID: 22301676
[TBL] [Abstract][Full Text] [Related]
14. Spleen tyrosine kinase as a molecular target for treatment of leukemias and lymphomas.
Uckun FM; Qazi S
Expert Rev Anticancer Ther; 2010 Sep; 10(9):1407-18. PubMed ID: 20836676
[TBL] [Abstract][Full Text] [Related]
15. Spleen tyrosine kinase inhibition attenuates airway hyperresponsiveness and pollution-induced enhanced airway response in a chronic mouse model of asthma.
Penton PC; Wang X; Amatullah H; Cooper J; Godri K; North ML; Khanna N; Scott JA; Chow CW
J Allergy Clin Immunol; 2013 Feb; 131(2):512-20.e1-10. PubMed ID: 22981792
[TBL] [Abstract][Full Text] [Related]
16. Steady state kinetics of spleen tyrosine kinase investigated by a real time fluorescence assay.
Papp E; Tse JK; Ho H; Wang S; Shaw D; Lee S; Barnett J; Swinney DC; Bradshaw JM
Biochemistry; 2007 Dec; 46(51):15103-14. PubMed ID: 18052078
[TBL] [Abstract][Full Text] [Related]
17. Generation of a novel system for studying spleen tyrosine kinase function in macrophages and B cells.
Miller AL; Zhang C; Shokat KM; Lowell CA
J Immunol; 2009 Jan; 182(2):988-98. PubMed ID: 19124742
[TBL] [Abstract][Full Text] [Related]
18. Discovery and development of spleen tyrosine kinase (SYK) inhibitors.
Singh R; Masuda ES; Payan DG
J Med Chem; 2012 Apr; 55(8):3614-43. PubMed ID: 22257213
[No Abstract] [Full Text] [Related]
19. Spleen tyrosine kinase suppresses osteoblastic differentiation through MAPK and PKCα.
Yoshida K; Higuchi C; Nakura A; Yoshikawa H
Biochem Biophys Res Commun; 2011 Aug; 411(4):774-9. PubMed ID: 21782794
[TBL] [Abstract][Full Text] [Related]
20. Co-expression network analysis identifies Spleen Tyrosine Kinase (SYK) as a candidate oncogenic driver in a subset of small-cell lung cancer.
Udyavar AR; Hoeksema MD; Clark JE; Zou Y; Tang Z; Li Z; Li M; Chen H; Statnikov A; Shyr Y; Liebler DC; Field J; Eisenberg R; Estrada L; Massion PP; Quaranta V
BMC Syst Biol; 2013; 7 Suppl 5(Suppl 5):S1. PubMed ID: 24564859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
